www.cerevel.com Open in urlscan Pro
34.73.75.90  Public Scan

Submitted URL: http://www.cerevel.com/
Effective URL: https://www.cerevel.com/
Submission: On October 11 via api from US — Scanned from DE

Form analysis 0 forms found in the DOM

Text Content

Skip to content Cerevel
 * About CerevelAbout Cerevel
   * Unraveling the mysteries of the brain
   * Leadership team
   * Partnerships
 * Our ProgramsOur Programs
   * Emraclidine
   * Darigabat
   * Tavapadon
   * CVL-871
 * Our ScienceOur Science
   * Our scientific strategy
   * Our pipeline
 * Investors & MediaInvestors & Media
   * Overview
   * News & EventsNews & Events
     * News & Announcements
     * Events
     * Presentations
   * StockStock
     * Stock quote & chart
     * Historic price lookup
     * Investment calculator
     * Analyst coverage
   * FinancialsFinancials
     * SEC filings
     * Annual reports
     * Quarterly results
   * GovernanceGovernance
     * Documents Charters
     * Leadership team
     * Committee Composition
   * ResourcesResources
     * Investor FAQs
     * Email alerts
     * Investor & Media Contact
 * CareersCareers
   * Working at Cerevel Therapeutics
   * Open Positions
   * Fellowship Programs
 * Contact Us


UNRAVELING THE MYSTERIES OF THE BRAIN TO TREAT NEUROSCIENCE DISEASES

Cerevel Therapeutics is working relentlessly to find paths through complexity in
an effort to bring real progress and new treatment options to people living with
some of the most devastating neuroscience diseases.


TRANSFORMING WHAT IS POSSIBLE IN NEUROSCIENCE

We are a team of experts purpose-built to make intentional, rigorously evaluated
decisions that are designed to deliver innovation in neuroscience.

Learn more




UNLOCKING NEW TREATMENT OPPORTUNITIES BY UNDERSTANDING HOW DEFICITS IN
NEUROCIRCUITRY DRIVE THE DEVELOPMENT OF SYMPTOMS

Devastating and life-threatening neuroscience diseases represent one of the
greatest opportunities of our time to help the hundreds of millions of people
affected worldwide. Addressing these underserved areas and communities is the
focus of our research and development efforts.

Learn more





OUR LATEST NEWS

 * Cerevel Therapeutics to Present at Morgan Stanley 20th Annual Global
   Healthcare Conference
   September 6, 2022
 * Cerevel Therapeutics Announces Pricing of $300 Million Private Offering of
   Convertible Senior Notes and Concurrent $254 Million Public Offering of
   Common Stock
   August 12, 2022
 * Cerevel Therapeutics Announces Pricing of $254 Million Public Offering of
   Common Stock and Concurrent $300 Million Private Offering of Convertible
   Senior Notes
   August 12, 2022



Read More



Cerevel
 * About CerevelAbout Cerevel
   * Unraveling the mysteries of the brain
   * Leadership team
   * Partnerships
 * Our ProgramsOur Programs
   * Emraclidine
   * Darigabat
   * Tavapadon
   * CVL-871
 * Our ScienceOur Science
   * Our scientific strategy
   * Our pipeline
 * Investors & MediaInvestors & Media
   * Overview
   * News & EventsNews & Events
   * StockStock
   * FinancialsFinancials
   * GovernanceGovernance
   * ResourcesResources
 * CareersCareers
   * Working at Cerevel Therapeutics
   * Open Positions
   * Fellowship Programs
 * Contact Us

 * Facebook
 * Twitter
 * LinkedIn
 * YouTube

Cerevel
 * Terms of Use
 * Privacy Policy
 * FCOI
 * Early Access Program (EAP) Policy

© 2022 Cerevel Therapeutics

CEREVEL and the CEREVEL logo are trademarks of Cerevel

Therapeutics. All Rights Reserved.



You are now leaving cerevel.com, a website provided by Cerevel Therapeutics. The
content displayed on external websites is not controlled by Cerevel, and Cervel
assumes no responsibility for the information or statements on external
websites.

Cancel OK